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Abstract 
Amyloid-β aggregation inhibitors are expected to be therapeutic or prophylactic agents for 
Alzheimer’s disease. Rosmarinic acid, which is one of the main aggregation inhibitors derived from 
Lamiaceae, was employed as a lead compound and its 25 derivatives were synthesized. In this study, 
the structure–activity relations of rosmarinic acid derivatives for the amyloid-β aggregation 
inhibitory effect (MSHTS assay), antioxidant properties, and xanthine oxidase inhibition were 
evaluated. Among the tested compounds, compounds 16d and 19 were found to the most potent 
amyloid aggregation inhibitors. The SAR revealed that the necessity of the presence of the phenolic 
hydroxyl on one side of the molecule as well as the lipophilicity of the entire molecule. The 
importance of these structural properties was also supported by docking simulations. 




Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in late adult 
life and accounts for 70 percent of dementia. The onset of AD leads to the progressive loss of 
learning ability and mental, behavioral and functional decline [1]. The number of the patients with 
AD is estimated to reach 150 million by 2050 due to the acceleration of demographic aging [2]. 
Choline esterase inhibitors (donepezil, galanthamine, rivastigmine) and an N-methyl-D-aspartic 
acid receptor antagonist (memantine) are now used for the medical treatment of AD. However, 
these treatments are used only for delaying the progression of AD [3]. Thus, the development of a 
fundamental AD treatment is becoming increasingly urgent.  
In the AD patient’s brain, the amyloid β (Aβ) protein is cut out of the amyloid precursor protein 
by the action of β-secretase and γ–secretase, is oligomerized, and becomes fibrotic by aggregation, 
finally forming senile plaques. This insoluble Aβ fiber is thought to induce neuronal death and 
cognitive dysfunction as a result of the deposition of senile plaques formed from the Aβ fiber in the 
vascular wall in the brain (the Aβ cascade hypothesis) [4].  Thus, Aβ aggregation inhibitors are 
expected to be therapeutic or prophylactic agents for AD. 
Previously, a series of bisphenols [5], alkaloids [6], polyphenols [7], and peptides with 
C-terminal motif of Aβ [8] have been reported as the target compound Aβ aggregation inhibitors. 
On the other hand, based on the demonstration of the correlation between the Aβ aggregation 
inhibitory activity and antioxidant activity [9], it appears that the study of the Aβ aggregation 
inhibitors based on the polyphenols can make a significant contribution to the development of AD 
treatment. For example, the relation between the structure of curcumin, an active polyphenol, and 
the Aβ aggregation inhibitory activity has been well-studied [10,11]. 
Recently, we established a novel method for the evaluation of the Aβ aggregation inhibitory 
activity called the “microliter scale high - throughput screening (MSHTS) system” [12], and 
showed that the results obtained by this method were comparable to those obtained using 
Thioflavin-T (ThT) assay, which is the standard method for the evaluation of the Aβ aggregation 
inhibitory activity. Using this new method, we found that of 52 tested spices, a member of 
Lamiaceae showed the strongest activity, and rosmarinic acid (1) isolated from Satureja hortensis 
(one of the species of Lamiaceae family) was a main Aβ aggregation inhibitor. Additionally, it was 
reported that rosmarinic acid led to an improvement in the cognitive function in Tg2576 mice [13].  
Rosmarinic acid (1) is also reported to show a high antioxidant activity [14]. Aβ-induced 
neuronal toxicity is regulated by the reactive oxygen species (ROS) generation that assists 
subsequent Aβ aggregation and speeds up the AD progression [15, 16] and antioxidants with 
catechol moiety showed to inhibit Aβ aggregation [17]. Thus, the relations between antioxidant 
activity and Aβ aggregation in the viewpoint of the compound structure is also of interest. 
Herein, we studied the structure–activity relations between the structures of rosmarinic acid 
derivatives and the Aβ aggregation inhibitory activity and also performed simulations of the 
docking of these derivatives with the Aβ monomer. Moreover, their potency as scavengers of the 
superoxide radical, produced by xanthine oxidase (XOD) (enzymatic method) and by the diphenyl 
picrylhydrazyl (DPPH) assay (chemical method) were also studied. 
 
2. Results and Discussion 
2.1 Chemistry 
Rosmarinic acid (1) has five key structural groups: a carboxy group, two phenol hydroxy groups, an 
unsaturated C–C bond, an alkoxy group, and an ester moiety (Fig. 1).  
 
(Single column fitting image) 
 Fig. 1. Key points in the structure of rosmarinic acid (1)  
 
Initially, we directed our attention to the carboxy group and prepared two analogs of rosmarinic 
acid, rosmarinic amide (2)[18,19] and caffeic acid 3,4-dihydroxyphenethyl ester (12c)[20,21,22] 
(Scheme 1). Rosmarinic amide (2) was synthesized using Won’s protocol [18,19]. However, since 
the yield obtained by this approach was quite poor, we attempted to synthesize it via an acid 
chloride prepared with oxalyl chloride and NH3 [23]. We attempted to prepare the caffeic acid 
3,4-dihydroxyphenethyl ester (12c) by the direct Mitsunobu reaction of 3,4-dihydroxyphenethyl 
alcohol with caffeic acid (3); however, the target yield was only 4.8%. Examination of the structure 
of 3,4-dihydroxyphenethyl alcohol shows that it possesses several alcohol groups that can function 
as a nucleophile in basic conditions. Additionally, the electrophilicity of the carboxy moiety of 
caffeic acid (3) was decreased because of the conjugation of the phenolic hydroxyls. Therefore, we 
planned to protect the phenolic hydroxyls in caffeic acid (3) and 3,4-dihydroxyphenethyl alcohol. 
The phenolic hydroxyls of 3,4-dihydroxyphenethyl alcohol were protected with 
tert-butyldimethylsilyl (TBS) groups, and the caffeic acid (3) phenolic hydroxyls were protected 
with the 2-nitrobenzensulfonyl (Ns) groups. NsO-groups exhibit an electron-withdrawing nature, 
and therefore the electrophilicity of the conjugated carboxy moiety was expected to be increased. In 
particular, caffeic acid (3) was esterified by Fischer’s ester synthesis and the phenolic hydroxyls 
were protected by the Ns groups, with acid hydrolysis of the ester giving carboxylic acid (6a). The 
coupling partner, the protected 3,4-dihydroxyphenethyl alcohol (10a), was synthesized from 3, 
4-dihydroxyphenylacetic acid (7). Allyl esterification of carboxylic acid (7) followed by 
TBS-protection of phenolic hydroxyls and reduction of the ester with lithium aluminum hydride 
gave alcohol (10a). Condensation of the protected carboxylic acid (6a) and alcohol (10a) followed 
by the deprotection of Ns and TBS groups gave caffeic acid 3,4-dihydroxyphenethyl ester (12c). 
 
(2-column-fitting image) 
Scheme 1. a) oxalyl chloride, NH3, THF, rt, 19.5 h; b) EDCI, DMAP, MeOH; c) NsCl, Et3N, 
CH3CN; d) AcOH, 0.5 M HCl; e) EDCI, DMAP, Allyl alcohol; f) TBSCl, imidazole, DMF; g) 
LiAlH4, THF; h) DEAD, TPP, THF, 0 °C → rt; i) PhSH, Cs2CO3, CH3CN, 0 °C → rt; j) TBAF, 
THF, 0 °C → rt; k) H2, Pd/C; l) DIAD, TPP, THF, 0 °C → rt 
 
Similarly, to investigate the effect of phenolic hydroxyls and unsaturated C–C bond, a series of 
carboxylic acids (6a, b) and alcohols (10a-c) were coupled, followed by deprotection to give esters 
(11a, 12a-d). Unsaturated C–C bond in compound 11a, 12a, and 12c were reduced by catalytic 
hydrogenation to give compounds 13a-c. 
Caffeic acid alkyl esters (16a-g, i, k) were also prepared by the condensation reaction of caffeic 
acid (3) and corresponding alkyl alcohols (15a-i) to study the effect of the aromatic ring on one side 
of the molecule (Scheme 2). Additionally, to confirm the effect of the ester group, ketone (19)[24] 
and amide (21a, b) were synthesized. 
 
(2-column-fitting image) 
Scheme 2. a) DIAD, PPh3, THF, r.t.; b) PhSH, Cs2CO3, CH3CN, 0 °C → rt; c) TBAF, THF, 0 °C 
→ rt; d) pyrolidine, AcOH, THF, reflux; e) iPr2NEt, DMAP, EDCI, DMF, rt 
 
2.2 Aβ(1-42) aggregation inhibitory activity 
Elucidation of the essential structural factor for the inhibition of the Aβ(1-42) aggregation 
inhibitory activity would lead to the development of more effective inhibitors and would obtain 
vital information for the elucidation of the inhibitory action mechanism. Therefore, we directed our 
attention to the five structural features of rosmarinic acid (1) that show the strong activity: carboxy 
group, phenolic hydroxyls, unsaturated C–C bond, alkoxy group, and ester moiety. We synthesized 
various derivatives and evaluated their Aβ(1-42) aggregation inhibitory activities (Table 1). 
 
 
Table 1. AE aggregation inhibitory activity by MSHTS system and CLogP values of 
rosmarinic acid derivatives  
 
 
First, we studied the effect of carboxy group on the activity. Compared to the Aβ(1-42) aggregation 
inhibitory activity of rosmarinic acid (1, EC50 = 20.3 µM), amide (2) and compound 12c, which 
eliminate the carboxylic acid, showed almost equivalent activities of 21.9 µM and 20.6 µM, 
respectively. This suggested that the carboxy group did not affect the activity. 
 Next, the effect of phenolic hydroxyls was evaluated. Compared to the EC50 value of compound 
12c (20.6 µM), the EC50 values of compound 12a, for which the phenolic hydroxyls on the 
carboxylic side were eliminated, and compound 12d, for which the phenolic hydroxyls on the 
Compounds EC50 [µM] CLogP Compounds EC50 [µM] CLogP
20.3 1.10 23.2 1.98
21.9 0.27 24.7 2.26
216 0.97 12.0 2.79
67.7 1.20 2.58 3.32
1040 4.56 5.13 3.85
7.95 3.30 10.4 4.38
39.5 2.96 9.52 5.43
20.6 2.03 80.1 1.33
8.41 3.30 54.8 1.86
4536 4.38 2.82 3.53
5.93 3.11 69.0 1.37



























alkoxy moiety were eliminated, were 7.95 and 8.41 µM, respectively. Thus, the activity was 
enhanced by the elimination of phenolic hydroxyls. However, interestingly, compound 11a, for 
which the phenolic hydroxyls on both sides were deleted, exhibited the activity of 1,040 µM. These 
results suggested that lateral phenolic hydroxyls on odd side were important for the activity.                 
Similarly, compound 12b, for which the phenolic hydroxyls were masked with methoxyl functional 
groups, showed significantly lower activity (EC50 = 39.5 µM) than compound 12c. In line with the 
results described above, in contrast to the activity of compound 13a (EC50 = 4,536 µM), for which 
the phenolic hydroxyls on both sides were eliminated, compound 13d, for which hydroxyl groups 
on the alkoxy side were masked with methoxy groups, showed a higher activity (EC50 = 274 µM). 
Moreover, compound 13b, for which the hydroxyls were present on the alkoxy side, showed 
significantly higher activity (EC50 = 5.93 µM) than compound 13d. These results suggested that not 
only the existence of polar functional groups but also the functional groups that could make 
hydrogen bonds or were hydrophilic affected the activity. 
To evaluate the effect of the aromatic rings on the activity, we tested the compounds for which one 
phenyl ring was substituted with an alkyl chain. Compound 16 (EC50 = 5.13 µM) for which the 
alkyl chain was as long as that of compound 12d showed almost the same activity as the parent 
compound. This result suggested that the existence of the aromatic ring was not important for the 
activity; rather, the presence of a hydrophobic group in the alkoxy moiety was vital.  
Next, the effect of the alcohol substitution for catechol was investigated. The activity of compound 
16k (EC50 = 54.8 µM) with alcohol in alkoxy moiety was significantly impaired when compared to 
compound 12c with catechol. This result suggested that catechol was important for the activity, 
seemingly contradicting the interpretation of the results for 16e and 12d. Nevertheless, this 
discrepancy may be resolved by considering the fact that it is easier for compound 12c with the 
catechol moiety to make a hydrophilic bond via π–π stacking than for compound 16k with the 
Aβ(1-42) peptide. 
We then investigated the effect of the alkyl chain length on the alkoxy moiety. The activity of 
caffeic acid alkyl esters was enhanced in accordance with the elongation of alkyl chain in the 1 to 5 
range. The activity was maximum at the C5-ester (16d, EC50 = 2.58 µM) and then decreased 
gradually. Thus, the length of the alkyl side chain (length of the liphophilic moiety) was important 
for the activity. 
The effect of the unsaturated C–C bond in the linker that connected the two catechols was 
investigated. Comparison of compounds 11a, 12a, and c with the α,β-unsaturated ester and 
compounds 13a, b, and c with the saturated ester showed that the activities of the corresponding 
compounds were almost equivalent. This suggested that the unsaturated bond in the linker was not 
important for the activity. 
The mode of connection linking the two catechols was then investigated. The activity of compounds 
21a (69.0 µM) and 21b (11.4 µM) that connected the carboxyl and alkoxy group via the amide were 
significantly impaired compared to the corresponding ester compounds 12c and 16d. On the other 
hand, the activity of ketone 19 (2.82 µM) was almost equivalent to that of compound 16d. These 
results suggested that the resonance effect of amide nitrogen may fix the conformation and affect 
the activity. 
 
2.3 Kinetics of Aβ(1-42) aggregation in the existence of inhibitors 
The aggregation of Aβ(1-42) was followed by an increase in the standard deviation (SD) value of 
fluorescence intensities owing to the variability of QDAβ(1-42) in coaggregates. The representative 
aggregation curve on Fig. 2 demonstrates a good fit between the Boltzmann equation used for 
fitting and experimental data that is confirmed by plotting the residuals versus time in the inset. 
Parallel measurements at 37°C with 30 µM Aβ(1-42) showed good reproducibility of the maximal 
SD of fluorescence 6.77 and the aggregation growth rate (k = 0.533 min-1) in the control (without 
inhibitor). The lag time of the reaction was 4.44 min. By contrast, by the addition of 20.3 µM 
(EC50) of rosmarinic acid (1) or 5.13 µM of C6-ester (16e), the maximal SD of fluorescence was 
3.40 and 3.68 and the aggregation growth rate (k = 0.508 and 0.190 min−1), without any change in 
the lag-period of the reaction, respectively. These results demonstrated that the existence of 
rosmarinic acid (1) did not affect the aggregation rate but reduced the total amount of aggregates 
and extended the lag time (5.58 min). On the contrary, the existence of C6-ester (16e) reduced the 
aggregation rate, the total amount of aggregates and lag-period (1.10 min). Thus, it was suggested 
that the mechanism of inhibition of rosmarinic acid (1) and C6-ester (16e) was different. 
 
(1 column fitting image) 
Fig. 2 Time-lapse analyses of process of Aβ(1-42) aggregation with/without 20.3 µM (EC50) of 
rosmarinic acid (1) or 5.13 µM of C6-ester (16e) obtained by MSHTS system. – –: control, --- ---: 
rosmarinic acid (1),    : C6-ester (16e) 
  
2.4 CLogP values of rosmarinic acid derivatives 
For exhibiting central nervous system (CNS) activity, compounds need to pass through the 
blood–brain barrier (BBB). One of the factors relevant to success of CNS drugs is lipophilicity. In 
the common logarithm of octanol/water partition coefficient (cLogP) that showed the degree of 
calculated lipophilicity from chemical structure, CNS drugs showed significantly higher value than 
that of peripheral drugs. The average cLogP value of existing CNS drugs was 3.43 [25]. ClogP 
values of the compounds were shown in Table 1. On comparing the EC50 values and cLogP values, 
the active compounds (12a, 12d, 13b, 16d, 16e, 19) tended to show suitable cLogP values (3.30, 
3.30, 3.11, 3.32, 3.85, 3.53, respectively). Thus, these compounds were expected to show the 
Aβ(1-42) aggregation inhibitory activity also in vivo. 
 
2.5 Docking simulation between rosmarinic acid derivatives and Aβ(1-42) monomer 
Clarifying the binding site of rosmarinic acid derivatives on Aβ(1-42), we would be able to presume 
important amino acid residues in Aβ(1-42) for aggregation and to design more effective inhibitors. 
Thus, docking simulation between Aβ(1-42) monomer (PDB: 1Z0Q)[26] and 25 of rosmarinic 
















The results were shown in S-1. Concerning the lowest energy cluster in 50 calculated clusters for 
each derivatives, the derivatives could be classified in three groups by the activity and binding site: 
1) derivatives with EC50 ≦ 10 µM tended to bind to amide NH and carboxylate in Ala42 with their 
phenolic hydroxyls via hydrogen bond (Fig. 3A); 2) derivatives with 10 µM < EC50 < 100 µM 
tended to bind to amide carbonyl oxygen in Ala30 with their phenolic hydroxyl via hydrogen bond 
(Fig. 3B); 3) derivatives with EC50 ≧ 100 µM tended to bind to side chain in His14 with their ester 
functional group via hydrogen bond (Fig. 3C). Concerning this result that higher effective 
derivatives tended to bind Ala42 with the report that Aβ(1-42) might aggregate faster than Aβ(1-40) 
[29], it was suggested that Ala42 played an important role in their aggregation process. 
  
(2 column fitting image) 
Fig. 3. Docking model between Aβ(1-42) monomer and rosmarinic acid derivatives calculated by 
AutoDock. 
 
 2.6 XOD inhibitory effect 
Among the 25 tested rosmarinic acid derivatives (Table 2), 10 displayed XOD inhibitory potencies. 
Compounds 2, 12c, 12d, 14, 16b, 16c, 16d, 16j, 16k, 19 showed better potencies. A detailed 
evaluation of the chemical structures of the active rosmarinic acid derivatives showed a general 
requirement for two or three hydrophilic moieties for better potency with compounds 2, 12c, 16i, k 
being the potent inhibitors in the tested compounds. Additionally, the activity of series of caffeic 
acid alkyl esters were depending on the length of alkyl side chain. Most potent derivatives were 
compound 16c and 16d (butyl and pentyl ester).  
 
Table 2. XOD inhibitory and DPPH radical-scavenging activity 
 XOD inhibition (%)  DPPH radical scavenging 
activity (%) 
compound 1 µM 10 µM 100 µM  100 µM 500 µM 
1  < 10 27  47 66 
2  38 82  39 48 
3  < 10 < 10  49 63 
8f  < 10 65  48 64 
11a  < 10 < 10  < 10 < 10 
12a  < 10 22  40 56 
12b  50 43  43 59 
12c  26 80  37 46 
12d  < 10 62  35 51 
13a  < 10 < 10  < 10 < 10 
13b  < 10 < 10  38 54 
13c  < 10 21  37 49 
13d  < 10 < 10  < 10 < 10 
16a  < 10 22  46 62 
16b  < 10 61  46 63 
16c  <10 > 90  46 62 
16d  11 > 90  46 62 
16e  10 < 10  45 61 
16f  11 25  46 63 
16g  < 10 40  45 61 
16i  < 10 84  41 54 
16k  < 10 51  42 55 
19  12 76  48 62 
21a  < 10 30  47 64 
21b  < 10 33  40 53 
allopurinol < 10 > 90     
edaravone     50-53 71-75 
 
2.7 Antioxidant ability (DPPH radical scavenging assay) 
The antioxidant activities of rosmarinic acid derivatives were based on their interaction with the 
2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical (Table 2) [30]. As expected, the results 
suggested that compounds without catechol type aromatic ring did not exhibit significant 
antioxidant activities, as it is shown by the low inhibition percentages at very high concentrations 
(<10% at 500 µM concentration). Thus, the significant radical scavenging activity of the tested 
compounds can be explained by the presence of catechol phenolic hydroxyls that are important in 
the scavenging action of ROS species. However, we could not find a specific structural feature of 




In summary, rosmarinic acid derivatives were synthesized and their Aβ(1-42) aggregation 
inhibitory activity was investigated. After detailed consideration of structure–activity relations, it 
was suggested that the structural requirement of rosmarinic acid derivatives to express the activity 
was phenolic hydroxyls in unilateral side and the length of the alkoxy moiety. 
Additionally, normally ester functional group was labile intravitally to hydrolases to metabolite to 
carboxylic acid and alcohol. Thus, the fact that compound 19 showed the equivalent activity to 
compound 16d gave us hope to develop in vivo experiment.  
Docking simulation of Aβ(1-42) monomer and rosmarinic acid derivatives by AutoDock suggested 
that potent Aβ aggregation inhibitor tend to dock the Ala42, Ile31, and Val39. This result suggested 
the importance of C-terminal of Aβ(1-42) for the aggregation. XOD inhibitory effect was affected 
by the compounds lipophilicity. DPPH antioxidation activity was found in the derivatives with 
catechol type moiety. 
The present study sheds new light on the properties of this interesting group of compounds. Further 
studies are now underway in our laboratory, including a search for more effective analogs and 
studies exploring the mechanism of action of these compounds. 
 
4. Experimental Part 
4.1 MSHTS system 
The EC50 values of compounds were determined by a modified MSHTS system [12]. More 
specifically, various concentrations of rosmarinic acid derivatives, 30 nM QD - labeled Aβ(1-42) 
(QDAβ(1-42)), and 30 µM Aβ(1-42) in PBS containing 5% EtOH and 3% DMSO were incubated 
in a 1536 - well plate at 37˚C for 24 h, and the formed QDAβ(1-42)–Aβ(1-42) coaggregates in each 
well were observed by an inverted fluorescence microscope equipped with a color CCD camera. 
SD values of fluorescence intensities of 10,000 pixels (100 × 100 pixels: 167 × 167 mm) in the 
central region of each well were measured by the ImageJ software. The SD values, which were 
approximately proportional to the amount of aggregates, were plotted against the concentrations of 
added rosmarinic acid derivatives to establish an inhibition curve. EC50 values were estimated from 
the inhibition curve using the EC50 shift by the Prism global fitting software. 
 
4.2 Data analysis and kinetic formation 
The kinetics of Aβ(1-42) aggregation could be described as sigmoid curves, and aggregation 
parameters were determined by fitting the plot of the SD values of fluorescence intensities versus 
time in the Boltzmann equation. 
              
               
, 
where SDmin is the initial SD level, SDmax is SD of maximal aggregation level, t50 is the time when 
fluorescence reaches half maximal, and k is the rate constant of aggregate formation. The lag time is 
calculated as 
            
4.2 Molecular Docking [27,28] 
AutoDock, PytonMolecularViewer, and Cygwin were used for the docking simulation of 
interactions between Aβ(1-42) and inhibitors. ChemBioDraw was used for the preparation of 
chemical structure data of inhibitors for the docking simulation. ChemBio3D was used for the 
calculation of molecular dynamics and the most stable conformation of inhibitors. The results of 
docking simulation were analyzed by using Discovery Studio. PDB: 1Z0Q [26] was used for the 
docking simulation with Aβ(1-42) aggregation inhibitors. The compounds used for the docking 
simulation were 25 rosmarinic acid derivatives.  
 
4.3 XOD inhibition test 
35 µL of phosphate buffer (100 mM, pH=7.6), 50 µL of a solution of allopurinol and rosmarinic 
acid derivatives in DMSO, 30 µL of a solution of XOD (from butter milk, Oriental Yeast Co., Ltd.) 
in phosphate buffer were added in 96 well micro plate. Then, 60 µL of a solution of 500 µM 
xanthine in phosphate buffer was added to the solution at rt. After 8 min, 1N HClaq was added and 
absorbance at 290 nm was measured. The inhibition rate (%) was calculated according to the 
following equation: 
                       
                                        
                              
      
 
4.4 1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay 
40 µL of 1 mM DPPH solution and 150 µL of EtOH were added to 96 well plate. Then, 10 µL of 2 
mM or 10 mM of edaravone, or rosmarinic acid derivatives in DMSO was added at rt. And then, the 
absorbance at 517 nm was continuously measured for 60 min, and radical trapping capacity was 
calculated with the data at 20 min following the equation: 
                                     
                      
                    
       
 
4.5 Typical reaction procedure for the construction of rosmarinic acid derivatives (12c) 
4.5.1 Methyl caffeate (4) 
A mixture of caffeic acid (309.2 mg, 1.72 mmol), EDCI (385.3 mg, 2.01 mmol) and DMAP (22.1 
mg, 0.181 mmol) in methyl alcohol (400 µL) was stirred at 60°C for 13 h. The resulting mixture 
was quenched with 2N HCl and extracted with AcOEt. The combined organic phases were washed 
with sat. NaHCO3, dried over anhydrous magnesium sulfate, and evaporated under reduced 
pressure. The residue was purified by column chromatography on silica gel (MeOH–CHCl3) (1:5 
v/v) to give a title compound (287.5 mg, 86%) as a white solid. Mp: 161°C–164°C [31], IR ṽ: 3489, 
3303, 2955, 2925, 1679, 1601, 1519 cm−1. 1H-NMR (500 MHz, acetone-d6) δ: 7.51 (d, 1H, J = 16.1 
Hz), 7.13 (d, 1H, J = 2.0 Hz), 7.02 (dd, 1H, J = 2.0, 8.0 Hz), 6.84 (d, 1H, J = 8.0 Hz), 6.26 (d, 1H, J 
= 16.1 Hz), 3.69 (s, 3H). 13C-NMR (125 MHz, acetone-d6) δ: 167.0, 147.9, 145.5, 144.9, 126.8, 
121.7, 115.6, 114.5, 114.4. High-resolution MS calcd. for C10H10O4 (M+): 194.0579. Found: 
194.0585. All spectral data agreed with previously reported data [32]. 
 
4.5.2 Methyl 3,4-bis[[(2-nitrophenyl)sulfonyl]oxy] cinnamate (5) 
To a solution of 4 (194.6 mg, 1.00 mmol) in CH3CN (2.2 mL) were added triethylamine (0.63 mL, 
4.50 mmol) and 2-nitrobenzenesulfonyl chloride (487.1 mg, 2.30 mmol) at 0°C. The mixture was 
stirred at 0°C for 0.5 h. The reaction mixture was quenched with 2M HCl and extracted with 
CH2Cl2. The combined organic phases were washed with brine, dried over anhydrous magnesium 
sulfate and evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel (AcOEt–n-hexane) (3:2 v/v) to give a title compound (562.9 mg, 99%) 
as white solid. Mp: 118°C–123°C, IR ṽ: 3099, 1714, 1542, 1390, 1191, 850, 814, 693 cm−1. 
1H-NMR (500 MHz, CDCl3) δ: 8.03 (dd, 2H, J = 1.3, 7.9 Hz), 7.89–7.84 (m, 2H), 7.81–7.74 (m, 
4H), 7.58 (d, 11H, J = 16.0 Hz), 7.48 (dd, 1H, J = 2.0, 8.5 Hz), 7.45 (d, 1H, J = 2.0 Hz), 7.36 (d, 1H, 
J = 8.5 Hz), 6.39 (d, 1H, J = 16.0 Hz), 3.82 (s, 3H). 13C-NMR (125 MHz, CDCl3) δ: 166.4, 148.2, 
148.1, 141.6, 141.4, 141.1, 136.0, 135.1, 132.5, 131.6, 128.2, 128.1, 127.8, 124.9, 123.4, 120.7, 
51.8.  
 
4.5.3 3,4-Bis[(2-nitrophenyl)sulfonyl]oxycinnamic acid (6) 
To a solution of 5 (113.3 mg, 0.20 mmol) in AcOH (3.1 mL) was added 0.5M HCl aq (3.1 mL) at 
0°C. The mixture was stirred at 85°C for 37 h. The reaction mixture was added H2O and extracted 
with AcOEt. The combined organic phases were washed with brine, dried over anhydrous 
magnesium sulfate and evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel (MeOH–CHCl3) (1:20 v/v) to give a title compound (110.4 mg, 99%) 
as white solid. Mp: 182°C–186°C, IR ṽ: 3104, 1687, 1544, 1378, 1355, 1180, 1124, 851, 821, 721 
cm-1. 1H NMR (500 MHz, acetone-d6): δ 8.12–8.04 (m, 6H), 7.97–7.92 (m, 2H), 7.79 (dd, 1H, J = 
2.1, 8.6 Hz), 7.67 (d, 1H, J = 2.1 Hz), 7.64 (d, 1H, J = 16.0 Hz), 7.41 (d, 1H, J = 8.6 Hz), 6.55 (d, 
1H, J = 16.0 Hz). 13C-NMR (125 MHz, acetone-d6) δ: 167.1, 148.49, 148.77, 142.3, 142.0, 141.8, 
137.3, 136.1, 133.44, 133.40, 132.1, 128.8, 128.0, 125.8, 125.5, 125.3, 124.3, 121.9, 78.7. 
High-resolution MS calcd for C21H14N2O12S2 (M+): 549.9988. Found: 549.9969.  
 
4.5.4 Allyl (3,4-dihydroxyphenyl)acetate (8) 
To a mixture of (3,4-dihydroxyphenyl)acetic acid (7, 1.01 g, 6.02 mmol), EDCI (1.38 g, 7.21 mmol) 
and DMAP (73.4 mg, 0.60 mmol) was added allyl alcohol (4.5 mL) at room temperature, then 
heated at 60°C for 2 h. The resulting mixture was quenched with 2N HCl and extracted with AcOEt. 
The combined organic phases were washed with sat. NaHCO3, dried over anhydrous magnesium 
sulfate and evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel (acetone–n-hexane) (1:5 v/v) to give a title compound (1.11 g, 89%) 
as yellow oil. IR ṽ: 3389, 1706, 1606, 1281, 988, 961, 795 cm−1. 1H NMR (500 MHz, acetone-d6): δ 
6.77 (d, 1H, J = 2.2 Hz), 6.73 (d, 1H, J = 8.2 Hz), 6.59 (dd, 1H, J = 2.2, 8.2 Hz), 5.93–5.85 (m, 1H), 
5.24 (dq, 1H, J = 1.6, 17.3 Hz), 5.13 (dq, 1H, J = 1.6, 10.6 Hz), 4.52 (dt, 2H, J = 1.6, 5.5 Hz), 3.47 
(s, 2H). 13C NMR (125 MHz, acetone-d6): δ 171.8, 145.6, 144.8, 133.5, 126.7, 121.5, 117.7, 117.1, 
115.9, 65.4, 40.8. High-resolution MS calcd for C11H12O4 (M+): 208.0736. Found: 208.0727. 
 
4.5.5 Allyl [3,4-bis(tert-butyldimethylsilyl)oxyphenyl]benezeneacetate (9) 
To a solution of compound 8 (1.06 g, 5.11 mmol), TBSCl (1.86 g, 12.3 mmol) and imidazole (1.75 
g, 25.7 mmol) in DMF (2.3 mL) was stirred at 0°C for 0.5 h. The reaction mixture was added sat. 
NH4Cl and extracted with AcOEt. The combined organic phases were washed with sat. NaHCO3 
and brine, dried over anhydrous magnesium sulfate, and evaporated under reduced pressure. The 
residue was purified by column chromatography on silica gel (AcOEt–n-hexane) (1:20 v/v) to give a 
title compound (2.16 g, 97%) as colorless oil. IR ṽ: 2930, 1739, 1228, 905, 836 cm−1. 1H NMR (500 
MHz, CDCl3): δ 6.79 (d, 1H, J = 2.0 Hz), 6.76 (d, 1H, J = 8.0 Hz), 6.71 (dd, 1H, J = 2.0, 8.0 Hz), 
5.91–5.84 (m, 1H), 5.24 (dq, 1H, J = 1.6, 17.2 Hz), 5.18 (dq, 1H, J = 1.3, 10.1 Hz), 4.58 (dt, 2H, J = 
1.4, 5.7 Hz), 3.51 (s, 2H), 0.99 (s, 9H), 0.98 (s, 9H), 0.193 (s, 6H), 0.188 (s, 6H). 13C NMR (125 
MHz, CDCl3): δ 171.5, 146.8, 146.1, 132.2, 127.0, 122.3, 122.2, 121.0, 118.2, 65.4, 40.8, 26.0, 18.5, 
−4.0. High-resolution MS calcd for C23H40O4Si2 (M+): 436.2466. Found: 436.2463. 
 
4.5.6 2-[3,4-bis(tert-butyldimethylsilyl)oxyphenyl]ethanol (10a)  
To a suspension of LiAlH4 (278.9 mg, 4.90 mmol) in THF (2.00 mL) at 0°C were added compound 
9 (2.13 g, 4.88 mmol) in THF (17.5 mL). The reaction mixture was stirred at room temperature for 
0.5 h. The mixture was filtered through a Celite pad and evaporated under reduced pressure. The 
residue was purified by column chromatography on silica gel (AcOEt–n-hexane) (1:4 v/v) to give a 
title compound (1.83 g, 98%) as colorless oil. IR ṽ: 3326, 2929, 1463, 980, 834 cm−1. 1H NMR (500 
MHz, CDCl3): δ 6.69 (d, 1H, J = 8.3 Hz), 6.62 (d, 1H, J = 2.0 Hz), 6.58 (dd, 1H, J = 2.0, 8.3 Hz), 
3.70 (t, 2H, J = 6.5 Hz), 2.66 (t, 2H, J = 6.5 Hz), 0.92 (s, 9H), 0.91 (s, 9H), 0.121 (s, 6H), 0.117 (s, 
6H). 13C NMR (125 MHz, CDCl3): δ 146.7, 145.4, 131.3, 121.84, 121.79, 120.1, 63.7, 38.5, 25.8, 




To a cooled (0°C) solution of 6a (278.5 mg, 0.51 mmol) and 10a (118.7 mg, 0.31 mmol) in dry 
THF (1.6 mL) were added PPh3 (205.5 mg, 0.78 mmol) and DEAD (0.12 mL, 0.78 mmol). The 
reaction mixture was stirred at room temperature for 21 h. Then, the reaction was worked up by 
removal of the solvent, redissolved on AcOEt, and extracted with sat. NaHCO3. The organic phase 
was washed with brine, dried over anhydrous magnesium sulfate, and evaporated under reduced 
pressure. The residue was purified by column chromatography on silica gel (AcOEt–CHCl3) (1:30 
v/v) to give a title compound (266.1 mg, 94%) as yellow-green solid. Mp: 57°C–61°C, IR ṽ: 2930, 
2858, 1714, 1544, 1471, 1391, 1193, 1128, 903, 827, 781 cm−1. 1H NMR (500 MHz, CDCl3): δ 
8.04–8.01 (m, 2H), 7.88–7.84 (m, 2H), 7.80–7.73 (m, 4H), 7.55 (d, 1H, J = 16.1 Hz), 7.47–7.45 (m, 
2H), 7.35 (d, 1H, J = 8.3 Hz), 6.77 (d, 1H, J = 8.2 Hz), 6.71 (d, 1H, J = 2.3 Hz), 6.68 (dd, 1H, J = 
2.3, 8.2 Hz), 6.37 (d, 1H, J = 16.1 Hz), 4.36 (t, 2H, J = 7.0 Hz), 2.88 (t, 2H, J = 7.0 Hz), 0.981 (s, 
9H), 0.979 (s, 9H), 0.192 (s, 6H), 0.189 (s, 6H). 13C NMR (125 MHz, CDCl3): δ 165.8, 148.2, 148.1, 
146.5, 245.4, 141.6, 141.3, 141.1, 135.9, 135.1, 132.4, 131.7, 130.6, 128.2, 128.2, 127.8, 124.9, 
1247, 123.4, 121.7, 121.6, 121.0, 120.965.5, 34.3, 25.8, 18.3, −4.2.  
 
4.5.8 2-(3,4-Dihydroxyphenyl)ethyl caffeate (12c) 
2-[3,4-bis(tert-butyldimethylsilyloxy)phenyl]ethyl caffeate  
To a suspension of Cs2CO3 (1.19 g, 3.55 mmol) in CH3CN (1.90 mL) were added thiophenol (0.18 
mL, 1.79 mmol) and 11d (132.2 mg, 0.14 mmol) at 0°C. The mixture was stirred at room 
temperature for 1.5 h. The reaction was quenched with sat. NH4Cl and extracted with AcOEt. The 
organic phase was dried over anhydrous magnesium sulfate and evaporated under reduced pressure. 
The residue was purified by column chromatography on silica gel (MeOH–CHCl3) (1:100 v/v) to 
give a title compound (64.6 mg, 82%) as yellow-green solid. Mp: 130°C–134°C, IR ṽ: 3463, 2929, 
1670, 1278, 980, 906, 836, 782 cm−1. 1H NMR (500 MHz, CDCl3): δ 7.56 (d, 1H, J = 16.1 Hz), 
7.08 (s, 1H), 7.60 (dd, 1H, J = 2.0, 8.0 Hz), 6.87 (d, 1H, J = 8.0 Hz), 6.76 (d, 1H, J = 8.0 Hz), 6.72 
(d, 1H, J = 2.0 Hz), 6.68 (dd, 1H, J = 2.0, 8.0 Hz), 6.25 (d, 1H, J = 16.1 Hz), 4.34 (t, 2H, J = 7.0 
Hz), 2.89 (t, 1H, J = 7.0 Hz), 0.98 (s, 18H), 0.19 (s, 12H). 13C NMR (125 MHz, CDCl3): δ 167.7, 
146.6, 146.3, 145.5, 150.0, 143.7, 130.8, 127.5, 122.4, 121.8, 121.7, 121.0, 115.6, 115.5, 114.4, 
65.4, 34.5, 25.9, 18.4, −4.1. High-resolution MS calcd for C29H44O6Si2 (M+): 544.2677. Found: 
544.2688. 
To a solution of above compound (60.4 mg, 0.11 mmol) in THF (3.6 mL) were added TBAF (1.1 M 
in THF) (0.40 mL, 0.44 mmol) at 0°C. The mixture was stirred at room temperature for 2.5 h. Then, 
the reaction was worked up by removal of the solvent, redissolved on AcOEt, and extracted with 
H2O. The organic phase was washed with brine, dried over anhydrous magnesium sulfate, and 
evaporated under reduced pressure. The residue was purified by column chromatography on silica 
gel (MeOH–CHCl3) (1:20 v/v) to give a title compound (29.6 mg, 84%) as white solid. Mp: 
118–120 ºC [28], IR ṽ: 3283, 1680, 1394, 1168, 853, 810 cm−1. 1H NMR (500 MHz, MeOH-d4): δ 
7.51 (d, 1H, J = 15.7 Hz), 7.02 (d, 1H, J = 2.0 Hz), 6.92 (dd, 1H, J = 2.0, 8.0 Hz), 6.76 (d, 1H, J = 
8.0 Hz), 6.70–6.68 (m, 2H), 6.56 (dd, 1H, J = 2.0, 8.0 Hz), 6.23 (d, 1H, J = 15.7 Hz), 4.27 (t, 2H, J 
= 7.2 Hz), 2.82 (t, 2H, J = 7.2 Hz). 13C NMR (125 MHz, MeOH-d4): δ 169.3, 149.5, 146.9, 146.8, 
146.2, 145.0, 144.9, 130.8, 127.7, 123.0, 121.2, 117.0, 116.5, 116.4, 115.1, 66.5, 35.6. 
High-resolution MS calcd for C17H16O4 (M+): 316.0947. Found: 316.0962. All spectral data agreed 
with previously reported data [33]. 
 
4.6 Calculation of cLogP value of tested compounds 
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